Compare $DMAC vs $SPRY | Chartloom

Compare

$DMAC vs $SPRY

DiaMedica Therapeutics Inc · ARS Pharmaceuticals Inc

DMAC

DiaMedica Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Compare $DMAC vs $SPRY

Comparing DiaMedica Therapeutics Inc and ARS Pharmaceuticals Inc

DMACDiaMedica Therapeutics Inc

SPRYARS Pharmaceuticals Inc

DMACDiaMedica Therapeutics Inc

Market cap

$449M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

5.0%

52W performance

19.7%

FCF yield

-7.0%

SPRYARS Pharmaceuticals Inc

Market cap

$420M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.81x

Rev growth (TTM)

4.1%

YTD performance

-63.2%

52W performance

-61.9%

FCF yield

-46.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

DMAC

SPRY

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

DMAC$449M

SPRY$420M

Enterprise Value

DMAC$444M

SPRY$509M

Price

DMAC$8.33

SPRY$4.23

P/E Ratio

DMACN/A

SPRYN/A

P/S Ratio

DMAC0.00x

SPRY3.59x

EV/Sales

DMAC0.00x

SPRY4.35x

EV/EBITDA

DMAC0.00x

SPRY0.00x

P/B Ratio

DMAC11.58x

SPRY32.35x

P/FCF Ratio

DMACN/A

SPRYN/A

EV/FCF

DMAC-14.07x

SPRY-2.59x

PEG Ratio

DMACN/A

SPRYN/A

Forward P/E (NTM)

DMACN/A

SPRYN/A

Forward P/S (NTM)

DMACN/A

SPRY2.81x

Revenue (TTM)

DMAC$0

SPRY$117M

Revenue Growth (YoY)

DMACN/A

SPRY4.1%

Forward Rev Growth

DMAC306.4%

SPRY46.9%

Gross Margin (TTM)

DMAC0.0%

SPRY71.4%

Operating Margin (TTM)

DMAC0.0%

SPRY0.0%

EBITDA Margin (TTM)

DMAC0.0%

SPRY-183.6%

Net Margin (TTM)

DMAC0.0%

SPRY-184.2%

FCF Margin (TTM)

DMACN/A

SPRY-168.1%

Net Income (TTM)

DMAC$-38M

SPRY$-215M

FCF (TTM)

DMAC$-32M

SPRY$-197M

EPS (TTM)

DMAC-$0.70

SPRY-$2.17

ROE (TTM)

DMAC-7768.0%

SPRY-25667.0%

ROA (TTM)

DMAC-6936.0%

SPRY-6963.0%

ROIC (TTM)

DMAC-7766.0%

SPRY-11943.0%

Cash

DMAC$5M

SPRY$8M

Debt

DMAC$9K

SPRY$97M

Net Cash/Debt

DMAC$5M

SPRY$-89M

Current Ratio (TTM)

DMAC6.72x

SPRY3.48x

Quick Ratio (TTM)

DMAC6.63x

SPRY3.13x

Debt/Equity (TTM)

DMAC0.00x

SPRY7.73x

Debt/Assets (TTM)

DMAC0.0%

SPRY0.0%

Interest Coverage (TTM)

DMACN/A

SPRYN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

SPRY0.00x

Beta

DMAC0.96

SPRY0.92

52W Performance

DMAC19.7%

SPRY-61.9%

YTD Performance

DMAC5.0%

SPRY-63.2%

% from 52W High

DMAC-20.1%

SPRY-67.8%

% from 52W Low

DMAC58.8%

SPRY6.1%

Asset Turnover (TTM)

DMAC0.00x

SPRY0.38x

FCF Yield (TTM)

DMAC-7.0%

SPRY-46.8%

Earnings Yield (TTM)

DMAC-8.4%

SPRY-51.3%

Dividend Yield (TTM)

DMACN/A

SPRYN/A

Rule of 40

DMAC0.0

SPRY-164.1

EV/GP/RG

DMACN/A

SPRY0.16

Ticker research

View DMAC research View SPRY research

Metric	DMAC DiaMedica Therapeutics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$449M	$420M
Enterprise Value	$444M	$509M
Price	$8.33	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.59x
EV/Sales	0.00x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	11.58x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.81x
Revenue & Growth
Revenue (TTM)	$0	$117M
Revenue Growth (YoY)	N/A	4.1%
Forward Rev Growth	306.4%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-183.6%
Net Margin (TTM)	0.0%	-184.2%
FCF Margin (TTM)	N/A	-168.1%
Net Income (TTM)	$-38M	$-215M
FCF (TTM)	$-32M	$-197M
EPS (TTM)	-$0.70	-$2.17
ROE (TTM)	-7768.0%	-25667.0%
ROA (TTM)	-6936.0%	-6963.0%
ROIC (TTM)	-7766.0%	-11943.0%
Financial Health
Cash	$5M	$8M
Debt	$9K	$97M
Net Cash/Debt	$5M	$-89M
Current Ratio (TTM)	6.72x	3.48x
Quick Ratio (TTM)	6.63x	3.13x
Debt/Equity (TTM)	0.00x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	0.92
52W Performance	19.7%	-61.9%
YTD Performance	5.0%	-63.2%
% from 52W High	-20.1%	-67.8%
% from 52W Low	58.8%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-7.0%	-46.8%
Earnings Yield (TTM)	-8.4%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View DMAC research	View SPRY research

Valuation

P/S Ratio

DMAC

0.00x

SPRY

3.59x

EV/FCF

DMAC

-14.07x

SPRY

-2.59x

Growth & revenue

Revenue Growth TTM

SPRY

4.1%

Forward Revenue Growth

DMAC

306.4%

SPRY

46.9%

Profitability & performance

Gross Margin

SPRY

71.4%

DMAC

0.0%

ROE

DMAC

-7768.0%

SPRY

-25667.0%

FCF Yield %

DMAC

-7.0%

SPRY

-46.8%

52-Week Performance

DMAC

19.7%

SPRY

-61.9%

Detailed metrics comparison

DMAC

DiaMedica Therapeutics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

DMAC$449M

SPRY$420M

Enterprise Value

DMAC$444M

SPRY$509M

Price

DMAC$8.33

SPRY$4.23

P/E Ratio

DMACN/A

SPRYN/A

P/S Ratio

DMAC0.00x

SPRY3.59x

EV/Sales

DMAC0.00x

SPRY4.35x

EV/EBITDA

DMAC0.00x

SPRY0.00x

P/B Ratio

DMAC11.58x

SPRY32.35x

P/FCF Ratio

DMACN/A

SPRYN/A

EV/FCF

DMAC-14.07x

SPRY-2.59x

PEG Ratio

DMACN/A

SPRYN/A

Forward P/E (NTM)

DMACN/A

SPRYN/A

Forward P/S (NTM)

DMACN/A

SPRY2.81x

Revenue (TTM)

DMAC$0

SPRY$117M

Revenue Growth (YoY)

DMACN/A

SPRY4.1%

Forward Rev Growth

DMAC306.4%

SPRY46.9%

Gross Margin (TTM)

DMAC0.0%

SPRY71.4%

Operating Margin (TTM)

DMAC0.0%

SPRY0.0%

EBITDA Margin (TTM)

DMAC0.0%

SPRY-183.6%

Net Margin (TTM)

DMAC0.0%

SPRY-184.2%

FCF Margin (TTM)

DMACN/A

SPRY-168.1%

Net Income (TTM)

DMAC$-38M

SPRY$-215M

FCF (TTM)

DMAC$-32M

SPRY$-197M

EPS (TTM)

DMAC-$0.70

SPRY-$2.17

ROE (TTM)

DMAC-7768.0%

SPRY-25667.0%

ROA (TTM)

DMAC-6936.0%

SPRY-6963.0%

ROIC (TTM)

DMAC-7766.0%

SPRY-11943.0%

Cash

DMAC$5M

SPRY$8M

Debt

DMAC$9K

SPRY$97M

Net Cash/Debt

DMAC$5M

SPRY$-89M

Current Ratio (TTM)

DMAC6.72x

SPRY3.48x

Quick Ratio (TTM)

DMAC6.63x

SPRY3.13x

Debt/Equity (TTM)

DMAC0.00x

SPRY7.73x

Debt/Assets (TTM)

DMAC0.0%

SPRY0.0%

Interest Coverage (TTM)

DMACN/A

SPRYN/A

Net Debt/EBITDA (TTM)

DMAC0.00x

SPRY0.00x

Beta

DMAC0.96

SPRY0.92

52W Performance

DMAC19.7%

SPRY-61.9%

YTD Performance

DMAC5.0%

SPRY-63.2%

% from 52W High

DMAC-20.1%

SPRY-67.8%

% from 52W Low

DMAC58.8%

SPRY6.1%

Asset Turnover (TTM)

DMAC0.00x

SPRY0.38x

FCF Yield (TTM)

DMAC-7.0%

SPRY-46.8%

Earnings Yield (TTM)

DMAC-8.4%

SPRY-51.3%

Dividend Yield (TTM)

DMACN/A

SPRYN/A

Rule of 40

DMAC0.0

SPRY-164.1

EV/GP/RG

DMACN/A

SPRY0.16

Ticker research

View DMAC research View SPRY research

Metric	DMAC DiaMedica Therapeutics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$449M	$420M
Enterprise Value	$444M	$509M
Price	$8.33	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	3.59x
EV/Sales	0.00x	4.35x
EV/EBITDA	0.00x	0.00x
P/B Ratio	11.58x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-14.07x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.81x
Revenue & Growth
Revenue (TTM)	$0	$117M
Revenue Growth (YoY)	N/A	4.1%
Forward Rev Growth	306.4%	46.9%
Profitability
Gross Margin (TTM)	0.0%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-183.6%
Net Margin (TTM)	0.0%	-184.2%
FCF Margin (TTM)	N/A	-168.1%
Net Income (TTM)	$-38M	$-215M
FCF (TTM)	$-32M	$-197M
EPS (TTM)	-$0.70	-$2.17
ROE (TTM)	-7768.0%	-25667.0%
ROA (TTM)	-6936.0%	-6963.0%
ROIC (TTM)	-7766.0%	-11943.0%
Financial Health
Cash	$5M	$8M
Debt	$9K	$97M
Net Cash/Debt	$5M	$-89M
Current Ratio (TTM)	6.72x	3.48x
Quick Ratio (TTM)	6.63x	3.13x
Debt/Equity (TTM)	0.00x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.96	0.92
52W Performance	19.7%	-61.9%
YTD Performance	5.0%	-63.2%
% from 52W High	-20.1%	-67.8%
% from 52W Low	58.8%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.38x
FCF Yield (TTM)	-7.0%	-46.8%
Earnings Yield (TTM)	-8.4%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-164.1
EV/GP/RG	N/A	0.16
Ticker research	View DMAC research	View SPRY research